Shuwen Cao

Shuwen Cao

Auto-generated profile, based on publicly available information

Shuwen Cao

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BIO Integration
Verified
Journal Article
Open access
XLXiuling Li
Xiuling Li
SLShunung Liang
Shunung Liang
CTChee Hwee Tan
Chee Hwee Tan
SCShuwen Cao
Shuwen Cao
XXXiaoding Xu
Xiaoding Xu
WTWei Tao
Wei Tao
Since time immemorial, plant derived natural products have been used for the treatment of various human diseases before the intervention of modern medicine. The basis of modern medicine is still being inspired from traditional medicine and therapies. However, despite their tremendous therapeutic potential, these natural drugs often have poor bioavailability, metabolic instability, and aqueous insolubility. These factors greatly impede a natural drug’s commercialization potential as a mainstream medicine. Therefore, the development of nanocarrier drug delivery systems is indispensable in overcoming the various constraints of the bottlenecks which occur with natural drugs. Of particular interest in this review are four plant materials endogenous to China with the common names of barrenwort or horny goat weed (Epimedium), Shu Di Huang (Rehmannia glutinosa, RG), ginseng (Panax ginseng), and Dong Quai or female ginseng (Angelica sinensis, AS), each having been scientifically investigated for a wide range of therapeutic uses as has been originally discovered from the long history of traditional usage and anecdotal information by local population groups in Asia. The integration of natural drugs from the East and nanocarrier drug delivery systems developed from the West is paving the way towards further accurate and efficient medicine therapy. We further discuss the potential benefits of these plants and the enhancement of their therapeutic efficacy by nanotechnology intervention.

4 December 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Globally, hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers and a leading cause of cancer-related death. We previously identified an immune evasion pathway whereby tumor cells produce retinoic acid (RA) to promote differentiation of intratumoral monocytes into protumor macrophages. Retinaldehyde dehydrogenase 1 (RALDH1), RALDH2, and RALDH3 are the three isozymes that catalyze RA biosynthesis. In this study, we have identified RALDH1 as the key driver of RA production in HCC and demonstrated the efficacy of RALDH1-selective inhibitors (Raldh1-INH) in suppressing RA production by HCC cells. Raldh1-INH restrained tumor growth in multiple mouse models of HCC by reducing the number and tumor-supporting functions of intratumoral macrophages as well as increasing T-cell infiltration and activation within tumors. Raldh1-INH also displayed favorable pharmacokinetic, pharmacodynamic, and toxicity profiles in mice thereby establishing them as promising new drug candidates for HCC immunotherapy.

2 February 2024
Verified
Other
Open access
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

2 February 2024
Verified
Other
Open access
PDF file
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Safetyscreen assay for C86 performed at eurofins.

2 February 2024
Verified
Other
Open access
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Supplementary Figure S3 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma

2 February 2024
Verified
Other
Open access
PYPengfei Yu
Pengfei Yu
SCShuwen Cao
Shuwen Cao
SYShyh-Ming Yang
Shyh-Ming Yang
BRBantukallu Ganesh Rai
Bantukallu Ganesh Rai
NMNatalia J. Martinez
Natalia J. Martinez
MHMalay Haldar
Malay Haldar
Supplementary Figure S7 from RALDH1 Inhibition Shows Immunotherapeutic Efficacy in Hepatocellular Carcinoma